NBRV Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 Jul 2023 @ 16:00):

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections...

Stats
Today's Volume	706 536
Average Volume	13 843.00
Market Cap	4.55M
EPS	$-4.50 ( 2023-08-10 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0722
ATR14	$0.181 (28.73%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-06	Hogan H Michael Iii	Buy	0
2023-06-30	Maggio David	Buy	0
2023-01-29	Gelone Steven P.	Sell	140	Ordinary Shares
2023-01-29	Schroeder Theodore R	Sell	431	Ordinary Shares
2023-01-06	Gelone Steven P.	Sell	5	Ordinary Shares

INSIDER POWER
20.46
Last 98 transactions
Buy: 1 927 900 \| Sell: 612 376

Volume Correlation

Long: 0.06 (neutral)

Short: 0.60 (weak)

Signal:(34.114) Neutral

Nabriva Therapeutics PLC Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nabriva Therapeutics PLC Correlation - Currency/Commodity

-0.44
( neutral )

-0.60
( weak negative )

0.00
( neutral )

0.38
( neutral )

0.18
( neutral )

0.10
( neutral )

Nabriva Therapeutics PLC Financials

Annual	2022
Revenue:	$35.67M
Gross Profit:	$7.09M (19.87 %)
EPS:	$-21.32

Q1	2023
Revenue:	$7.59M
Gross Profit:	$3.15M (41.53 %)
EPS:	$-2.85

Q4	2022
Revenue:	$10.44M
Gross Profit:	$-5.91M (-56.61 %)
EPS:	$-8.49

Q3	2022
Revenue:	$8.78M
Gross Profit:	$4.37M (49.73 %)
EPS:	$-4.21

Financial Reports:

No articles found.

Nabriva Therapeutics PLC

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.